Intensive Care Unit and Secondary and Primary Immune Deficiency

Primary Immune Deficiency Disorder Clinical Trial

— ICUSPID  

Official title:

Intensive Care Unit and Secondary and Primary Immune Deficiency

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02888535
• Other study ID #: 2014-A01246-41
• Status: Completed
• Start date: January 2015
• Est. completion date: December 2019

Study information

• Verified date: July 2017
• Source: University Hospital, Caen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Primary immune deficiencies (PID) are characterized by a failure of the immune system that is not explained by any infectious, neoplastic, or iatrogenic cause. In 2015, more than 300 different inherited rare disorders were described. The occurrence of PID in adult is rare and diagnosis may be supported by the 6 ESID signs for adult. However these warnings signs are based only on expert recommendations and do not include comprehensive symptoms of PIDs. Recurrent infections, more aggressive, are the most common mode of revelation of the PID. Less frequently, autoimmune manifestation, solid tumor, lymphoproliferation tumor, chronic granulomatosis or hemophagocytic lymphohistiocytosis syndrome (HLS) may also revealed a PID. The objective of this study was to evaluate the occurrence of unknown PID in adult admitted in critical care unit and to determinate if the investigation of PID in patients with severe infections or HLS should be routinely performed in MCIU.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: December 2019
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Aged 18-65

• Hospitalized in medical intensive care unit for :

• Severe infection without pathogen identification

• Severe infection due to encapsuled pathogen

• Opportunistic infections or unusual pathogen

• Idiopathic hemophagocytic syndrome

Exclusion Criteria:

• primary immunodeficiency already known

• secondary immunodeficiency already known (HIV, cancer, immunosuppressive or immunomodulatory treatment, nephrotic syndrome, protein-losing enteropathy, severe malnutrition before admission, cirrhosis with hepatic failure, sickle cell disease, splenectomy and moderate chronic renal failure (clearance between 30 and 59 m² min/1.73 ml)

• local-regional factors which can be responsible for infections (history of ear, nose and throat surgery or neurosurgery, history of fracture of the skull base, cystic fibrosis, chronic respiratory insufficient)

Related Conditions & MeSH terms

• Immunologic Deficiency Syndromes
• Primary Immune Deficiency Disorder
• Primary Immunodeficiency Diseases

Intervention

Other:
• Internal Medicine consultation

Locations

Country	Name	City	State
France	Caen University Hospital	Caen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary objective : Number of patients with primary immune deficiency diagnosed after an admission in intensive care unit.	A consultation in the Internal Medicine department is schduled 3 months after the hospitalization in intensive care unit to investigate an immune deficiency. This consultation consit on a physical examination and a immune testing. Immune testing included but is not limited to : Complete blood count, blood smear Immunoglobulin (Ig) isotype and IgG sub class quantitation (gram per litre) Quantitative serum complement (C3 (milligram per litre), C4 (milligram per litre), CH50 (%) and AP50 when Neisseria meningitides infection) Extensive immunophenotyping of T, B, and natural killer cells (cells/mm3) Specific antibody response to a variety of vaccine (milligram/litre) HIV serology Body computed tomography (CT) scan Lymphocytes, macrophage functional assays or genetic assay when necessary The outcome measure is the number of participants with abnormal laboratory or radiology values leading to primary immune deficiency diagnosis	A consultation in the Internal Medicine Department is scheduled 3 months after admission in intensive care unit
Secondary	Secondary objectives : Number of patients diagnosed for a secondary immunodeficiency after admission in intensive care unit	A consultation in the Internal Medicine department is schduled 3 months after the hospitalization in intensive care unit to investigate an immune deficiency. This consultation consit on a physical examination and a immune testing. Immune testing included but is not limited to : Complete blood count, blood smear Immunoglobulin (Ig) isotype and IgG sub class quantitation (gram per litre) Quantitative serum complement (C3 (milligram per litre), C4 (milligram per litre), CH50 (%) and AP50 when Neisseria meningitides infection) Extensive immunophenotyping of T, B, and natural killer cells (cells/mm3) Specific antibody response to a variety of vaccine (milligram/litre) HIV serology Body computed tomography (CT) scan Lymphocytes, macrophage functional assays or genetic assay when necessary The outcome measure is the number of participants with abnormal laboratory or radiology values leading to secondary immune deficiency diagnosis	A consultation in the Internal medicine department is scheduled 3 months after admisson in intensive care unit